CRC Research Update — October 31, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Saturday, October 31, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
SCREENING
New Zealand bowel screening program linked to 61% drop in emergency colorectal cancer presentationsFollowing national rollout, acute CRC presentations fell from 9.71 to 3.79 per 100,000 population, with fewer metastatic cases and lower one-year mortality. (ANZ J Surg)
-
TREATMENT
Circulating tumor DNA monitoring may guide treatment for metastatic CRC with small lung nodulesIn a 70-patient prospective cohort, ctDNA clearance after treatment was associated with longer progression-free survival (12.6 vs. 6.8 months) and detected extrapulmonary spread a median of 5.5 months before imaging. (Eur J Cancer)
-
TREATMENT
Network meta-analysis compares refractory-line options in KRAS-mutant metastatic CRCAnalysis of 10 trials (3,959 patients) found fruquintinib, regorafenib, and TAS-102 all improved overall survival versus placebo; in KRAS-mutant tumors, fruquintinib and TAS-102 showed numerically favorable estimates, though indirect comparisons did not demonstrate superiority. (Front Oncol)
Today's research spans screening impact, liquid biopsy applications, and emerging insights into survivorship and treatment resistance.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data